Drug Profile
Belinostat - Valerio Therapeutics
Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator TopoTarget
- Developer Acrotech Biopharma; CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Servier; TopoTarget; Valerio Therapeutics
- Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- Phase II B-cell lymphoma; Glioblastoma
- Phase I/II Non-small cell lung cancer
- Suspended Chondrosarcoma
- No development reported Acute myeloid leukaemia; Bladder cancer; Breast cancer; Carcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Fallopian tube cancer; Liver cancer; Lymphoma; Malignant thymoma; Malignant-mesothelioma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)